About
About Torii Pharmaceutical Co., Ltd
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents for renal diseases and hemodialysis, such as ENAROY tablets to treat anemia associated with CKD; Riona tablets for the treatment of hyperphosphatemia/iron deficiency anemia (IDA); and REMITCH, an oral therapeutic agent for the treatment of pruritus. The company provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; VTAMA cream, a topical treatment for atopic dermatitis and plaque psoriasis; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. It markets its products primarily through medical representatives for medical professionals. The company has a collaboration with ALK-Abelló A/S to develop and commercializes ALK's allergen immunotherapy drug targeting pollen diseases caused by grass pollen. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
Visit company website
5 years, 6 months ago
Torii Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 18.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.0.
Torii Pharmaceutical Co., Ltd's total revenue sank by 1.3% to $12B since the same quarter in the previous year.
Its net income has increased by 9.5% to $987M since the same quarter in the previous year.
Based on the above factors, Torii Pharmaceutical Co., Ltd gets an overall score of 2/5.